title: Morphological changes of the pancreas in course of acute pancreatitis during treatment with Ulinastatin.
abstract: Acute pancreatitis is a severe clinical conditio that causes significant mortality in patients. Since we do not have at the moment effective causal treatment research on the use of pro tease inhibitors can produce tangible benefits. In view of the growing number of cases and high mortality in severe AP with one hand, and the lack of a usal treatment research efforts undertaken to search for effective drugs for this disease seem to have deep reasons.
  
  
  OBJECTIVE
  was to determine the histopathological changes in the pancreas in the treatment of acute pancreatitis with Ulinastatin.
  
  
  METHODS
  The study was conducted in male Wistar rats weighing 250-300 grams. 150 individuals were used for the experiment, 60 of them were treated with Ulinastatin. Experimental acute pancreatitis was induced by the model proposed by Aho and Henckel using sodium taurocholate. Ulinastatin dose numer depended on the duration of the experiment. For histopathological examination pancreatic fragments weighing approximately 1 g each were taken. Assessment and documentation of histopathological preparations were made by light microscopy.
  
  
  RESULTS
  Evaluation of the histological preparations of various time groups showed significantly improved results after application of Ulinastatin, depending on the duration of the inflammation and the number of doses of the drug.
  
  
  CONCLUSIONS
  Application for the treatment of UTI leads to inhibition of the inflammatory process at the stage of pancreatic edema and in cases of severe necrotizing course limits the progression of the disease which gives grounds for its clinical use in humans.
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Wallner
authors.forename: Michał
authors.initials: M
authors.lastname: Solecki
authors.forename: Ryszard
authors.initials: R
authors.lastname: Ziemiakowicz
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Ćwik
authors.forename: Przemysław
authors.initials: P
authors.lastname: Dyndor
authors.forename: Ryszard
authors.initials: R
authors.lastname: Maciejewski
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D018450:Disease Progression; D006023:Glycoproteins / Q000627:therapeutic use*; D008297:Male; D010179:Pancreas / Q000187:drug effects* / Q000473:pathology; D010195:Pancreatitis / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology*; D010940:Plant Proteins / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D013656:Taurocholic Acid
chemical_list: D006023:Glycoproteins; D010940:Plant Proteins; C052160:trypsin inhibitor, Zea mays; D013656:Taurocholic Acid; C028665:urinastatin